Cell therapy has shown impressive effects in experimental cardiomyopathy models. To a lesser extent, gene therapy has also been studied. In both cases, translation to clinical therapy has been disappointing. This paper is intended to describe the experience and achievements of a multicenter working group located in Porto Alegre, southern Brazil, in experimental and translational research projects for cell-based and gene therapy methods in the treatment of dilated and ischemic cardiomyopathies. The results of preclinical and clinical studies showed that bone marrow mononuclear stem cells indeed have an effect in improving myocardial perfusion and contractile function, but the overall results are poorly translated to the clinical level. Gene therapy studies with direct myocardial injections of naked VEGF 165 plasmid showed improvement in myocardial perfusion and function in animal models. A randomized clinical trial found that this method is safe and improved myocardial perfusion, but the benefits disappeared after 1 year. An animal experiment associating VEGF 165 with angiopoietin was undertaken in mini pigs to extend the durability of that therapy. In conclusion, our efforts to better understand the mechanisms and functions of gene and cell-based therapies in cardiology resulted in significant findings and propose a future look at cell-free therapeutic approaches.
Subscribe to Journal
Get full journal access for 1 year
only $68.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:368–76.
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315–22.
Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA. 2011;306:1669–78.
Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113:810–34.
Dawn B, Zuba-Surma EK, Abdel-Latif A, Tiwari S, Bolli R. Cardiac stem cell therapy for myocardial regeneration. A clinical perspective. Minerva Cardioangiol. 2005;53:549–64.
Leri A, Rota M, Pasqualini FS, Goichberg P, Anversa P. Origin of cardiomyocytes in the adult heart. Circ Res. 2015;116:150–66.
Retraction Watch. https://retractionwatch.com/2018/11/21/journals-stamp-expressions-of-concern-on-papers-from-anversas-cardiac-stem-cell-lab. Accessed 7 Dec 2018.
Planat-Benard V, Silvestre JS, Cousin B, André M, Nibbelink M, Tamarat R, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 2004;109:656–63.
Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701–5.
Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002;106:1913–8.
Metra M, Teerlink JR. Heart failure. Lancet 2017;390:1981–95.
Mensah GA, Wei GS, Sorlie PD, Fine LJ, Rosenberg Y, Kaufmann PG, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res 2017;120:366–80.
Cheng K, Sainsbury P, Fisher M, de Silva R. Management of refractory angina pectoris. Eur Cardiol. 2016;11:69–76.
Thadani U. Recurrent and refractory angina following revascularization procedures in patients with stable angina pectoris. Coron Artery Dis. 2004;15:1–4.
Bokeriya LA, Golukhova EZ, Eremeeva MV, Aslanidi IP, Merzlyakov VY, Georgiev GP, et al. Use of human VEGF (165) gene for therapeutic angiogenesis in coronary patients: first results. Bull Exp Biol Med 2005;140:106–12.
Kalil RA, Salles FB, Giusti II, Rodrigues CG, Han SW, Sant’Anna RT, et al. VEGF gene therapy for angiogenesis in refractory angina: phase I/II clinical trial. Rev Bras Cir Cardiovasc. 2010;25:311–21.
Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800–4.
Eibel B, Rodrigues CG, Giusti II, Nesralla IA, Prates PR, Sant’Anna RT, et al. Gene therapy for ischemic heart disease: review of clinical trials. Rev Bras Cir Cardiovasc. 2011;26:635–46.
Hulot JS, Ishikawa K, Hajjar RJ. Gene therapy for the treatment of heart failure: promise postponed. Eur Heart J. 2016;37:1651–8.
Hashimoto H, Olson EN, Bassel-Duby R. Therapeutic approaches for cardiac regeneration and repair. Nat Rev Cardiol. 2018;15:585–600.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
Giusti II, Rodrigues CG, Salles FB, Sant’Anna RT, Eibel B, Han SW, et al. High doses of vascular endothelial growth factor 165 safely, but transiently, improve myocardial perfusion in no-option ischemic disease. Hum Gene Ther Methods. 2013;24:298–306.
Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 2017;36:1037–46.
McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res 2017;121:731–48.
Shore S, Grau-Sepulveda MV, Bhatt DL, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Characteristics, treatments, and outcomes of hospitalized heart failure patients stratified by etiologies of cardiomyopathy. JACC Heart Fail. 2015;3:906–16.
Mestroni L, Rocco C, Gregori D, Sinagra G, Di Lenarda A, Miocic S, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol. 1999;34:181–90.
Ehlert FA, Cannom DS, Renfroe EG, Greene HL, Ledingham R, Mitchell LB, et al. Comparison of dilated cardiomyopathy and coronary artery disease in patients with life threatening ventricular arrhythmias: differences in presentation and outcome in the AVID registry. Am Heart J. 2001;142:816–22.
Saxon LA, De Marco T. Arrhythmias associated with dilated cardiomyopathy. Card Electrophysiol Rev. 2002;6:18–25.
Guarita-Souza LC, Carvalho KA, Woitowicz V, Rebelatto C, Senegaglia A, Hansen P, et al. Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation. 2006;114:120–4.
Jenkins GR, Lee T, Moland CL, Vijay V, Herman EH, Lewis SM, et al. Sex-related differential susceptibility to doxorubicin-induced cardiotoxicity in B6C3F1 mice. Toxicol Appl Pharmacol. 2016;310:159–74.
Kodama M, Zhang S, Hanawa H, Saeki M, Inomata T, Suzuki K, et al. Effects of 15-deoxyspergualin on experimental autoimmune giant cell myocarditis of the rat. Circulation 1995;91:1116–22.
Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation. 2005;112:1128–35.
Psaltis PJ, Carbone A, Nelson AJ, Lau DH, Jantzen T, Manavis J, et al. Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischaemic cardiomyopathy. JACC Cardiovasc Interv. 2010;3:974–83.
Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005;111:2198–202.
Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, et al. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res 2013;112:165–73.
Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA. 2001;98:10344–49.
Tao Z, Tan S, Chen W, Chen X. Stem cell homing: a potential therapeutic strategy unproven for treatment of myocardial injury. J Cardiovasc Transl Res. 2018;11:403–11.
Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ. Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. Circ Res 2016;118:95–107.
Kajstura J, Rota M, Whang B, Cascapera S, Hosoda T, Bearzi C, et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 2005;96:127–37.
Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003;107:2294–302.
Traverse JH, Henry TD, Pepine CJ, Willerson JT, Chugh A, Yang PC. TIME Trial: effect of timing of stem cell delivery following ST-elevation myocardial infarction on the recovery of global and regional left ventricular function: final 2-year analysis. Circ Res 2018;122:479–88.
Gyöngyösi M, Haller PM, Blake DJ, Martin Rendon E. Meta-analysis of cell therapy studies in heart failure and acute myocardial infarction. Circ Res 2018;123:301–8.
Zhang S, Ge J, Sun A, Xu D, Qian J, Lin J, et al. Comparison of various kinds of bone marrow stem cells for the repair of infarcted myocardium: single clonally purified non593 hematopoietic mesenchymal stem cells serve as a superior source. J Cell Biochem. 2006;99:1132–47.
Rickard J, Johnston DR, Price J, Tedford R, Baranowski B, Bassiouny M, et al. Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads. Heart Rhythm 2015;12:517–23.
Kalil RA, Ott D, Sant’Anna R, Dias E, Marques-Pereira JP, Delgado-Cañedo A, et al. Autologous transplantation of bone marrow mononuclear stem cells by mini-thoracotomy in dilated cardiomyopathy: technique and early results. Sao Paulo Med J 2008;126:75–81.
Sant’Anna RT, Fracasso J, Valle FH, Castro I, Nardi NB, Sant’Anna JR, et al. Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective randomized controlled trial. Rev Bras Cir Cardiovasc. 2014;29:437–47.
Lu Y, Wang Y, Lin M, Zhou J, Wang Zi, Jiang M, et al. A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Res Ther 2016;7:186.
Sant’anna RT, Kalil RA, Pretto Neto AS, Pivatto Júnior F, Fracasso J, Sant’Anna JR, et al. Global contractility increment in nonischemic dilated cardiomyopathy after free wall only intramyocardial injection of autologous bone marrow mononuclear cells: an insight over stem cells clinical mechanism of action. Cell Transplant 2010;19:959–64.
Neef K, Choi YH, Weichel A, Rahmanian PB, Liakopoulos OJ, Stamm C, et al. The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness. Cytotherapy 2012;14:670–8.
Ghem C, Dias LD, Sant’Anna RT, Kalil RAK, Markoski M, Nardi NB. Combined analysis of endothelial, hematopoietic, and mesenchymal stem cell compartments shows simultaneous but independent effects of age and heart disease. Stem Cells Int. 2017;2017:5237634.
Dias LD, Casali KR, Ghem C, da Silva MK, Sausen G, Palma PB, et al. Mesenchymal stem cells from sternum: the type of heart disease, ischemic or valvular, does not influence the cell culture establishment and growth kinetics. J Transl Med. 2017;15:161.
Eibel B, Kristochek M, Peres TR, Dias LD, Dartora DR, Casali KR, et al. β-Blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats. Cardiovasc Ther 2018;36:e12434.
Kristocheck M, Dias LD, Ghem C, Eibel B, Kalil RAK, Markoski MM. The homing of bone marrow stem cells is differentially activated in ischemic and valvular heart diseases and influenced by beta-blockers. J Transl Med. 2018;16:133.
Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013;346:f55.
Sarkar N, Rück A, Källner G, Y-Hassan S, Blomberg P, Islam KB, et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease—12-month follow-up: angiogenic gene therapy. J Intern Med. 2001;250:373–81.
Fortuin DF, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ, et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol. 2003;92:436–9.
Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009;17:1109.
Kalil RA, Teixeira LA, Mastalir ET, Moreno P, Fricke CH, Nardi NB. Experimental model of gene transfection in healthy canine myocardium: perspectives of gene therapy for ischemic heart disease. Arq Bras Cardiol. 2002;79:223–32.
Furlani AP, Kalil RA, Castro I, Cañedo-Delgado A, Barra M, Prates PR, et al. Effects of therapeutic angiogenesis with plasmid VEGF165 on ventricular function in a canine model of chronic myocardial infarction. Rev Bras Cir Cardiovasc. 2009;24:143.
Rodrigues CG, Plentz RDM, Dipp T, Salles FB, Giusti II, Sant’Anna RT, et al. VEGF 165 gene therapy for patients with refractory angina: mobilization of endothelial progenitor cells. Arq Bras Cardiol. 2013;101:149–53.
Eibel B, Markoski MM, Rodrigues CG, Dipp T, de Salles FB, Giusti II, et al. VEGF gene therapy cooperatively recruits molecules from the immune system and stimulates cell homing and angiogenesis in refractory angina. Cytokine 2017;91:44–50.
Oliveira ALA, Scheffer JP, Markoski M, Koche A, Balbinot A, Antunes F, et al. Vascular endothelial growth factor association with angiopoietin 1 promotes improvement in ventricular function after ischemic cardiomyopathy induced in mini pigs. Acta Cir Bras. 2018;33:386–95.
Banerjee MN, Bolli R, Hare JM. Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions. Circ Res 2018;123:266–87.
Suzuki E, Fujita D, Takahashi M, Oba S, Nishimatsu H. Therapeutic effects of mesenchymal stem cell-derived exosomes in cardiovascular disease. Adv Exp Med Biol. 2017;998:179–85.
Arzouni AA, Vargas-Seymour A, Rackham CL, Dhadda P, Huang GC, Choudhary P, et al. Mesenchymal stromal cells improve human islet function through released products and extracellular matrix. Clin Sci. 2017;131:2835–45.
Seth S, Narang R, Bhargava B, Ray R, Mohanty S, Gulati G, et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial. J Am Coll Cardiol. 2006;48:2350–51.
Henry TD, Traverse JH, Hammon BL, East CA, Bruckner B, Remmers AE, et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res 2014;115:730–7.
Martino H, Brofman P, Greco O, Bueno R, Bodanese L, Clausell N, et al. Multicentre, randomized, double blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart Study). Eur Heart J. 2015;36:2898–904.
Hamshere S, Arnous S, Choudhury T, Choudry F, Mozid A, Yeo C, et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. Eur Heart J. 2015;36:3061–9.
These studies were funded by Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Financiadora de Estudos e Projetos (FINEP), and Ministério da Saúde/Departamento de Ciência e Tecnologia (MS/DECIT).
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sant’Anna, R.T., Eibel, B., Markoski, M.M. et al. Gene therapy for refractory angina and cell therapy for heart failure: experience of a Brazilian research group. Gene Ther 27, 40–50 (2020). https://doi.org/10.1038/s41434-019-0087-2
Biosensors and Bioelectronics (2020)